GOA Therapeutics Corp — SEC Form D Filing
GOA Therapeutics Corp filed an SEC Form D on November 5, 2026, reporting $300K raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- November 5, 2026
- Amount reported
- $300K
- Round stage
- Pre-seed, based on an initial $300,000 equity financing round to fund early preclinical development.
- Industry
- Pharmaceuticals
- Website
- https://goathera.com/**
What the company does
Securities: Equity. Revenue: No Revenues. Exemption: Rule 506(c). Incorporated: DELAWARE
Problem
Acute alcohol intoxication and alcohol poisoning lack fast-acting targeted therapeutics, leaving healthcare providers reliant on passive supportive care to clear toxic blood alcohol levels.
Solution
GOA Therapeutics develops GOA26, an investigational drug candidate designed to rapidly lower blood alcohol concentration and sequester toxic acetaldehyde during acute poisoning events.
Why now
Increasing hospital emergency department admissions related to severe alcohol toxicity have created urgent demand for active pharmacological interventions that accelerate metabolic clearance.
Source: SEC EDGAR Form D filing